Vincristine + Carboplatin + Etoposide — Competitive Intelligence Brief

Vincristine + Carboplatin + Etoposide (Vincristine + Carboplatin + Etoposide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vinca alkaloid, platinum-based alkylating agent, topoisomerase inhibitor. Area: Oncology.

phase 3 Vinca alkaloid, platinum-based alkylating agent, topoisomerase inhibitor Microtubules, DNA Oncology Small molecule

Target snapshot

Vincristine + Carboplatin + Etoposide (Vincristine + Carboplatin + Etoposide) — St. Jude Children's Research Hospital. Vincristine is a vinca alkaloid that inhibits microtubule formation, disrupting cell division. Carboplatin is a platinum-based alkylating agent that cross-links DNA, causing cell death. Etoposide is a topoisomerase inhibitor that prevents DNA replication and transcription.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vincristine + Carboplatin + Etoposide TARGET	Vincristine + Carboplatin + Etoposide	St. Jude Children's Research Hospital	phase 3	Vinca alkaloid, platinum-based alkylating agent, topoisomerase inhibitor	Microtubules, DNA
docetaxel, cisplatin, and capecitabine	docetaxel, cisplatin, and capecitabine	Sun Yat-sen University	phase 3	Taxane, Platinum-based chemotherapeutic, Antimetabolite	Microtubules, DNA
docetaxel, nedaplatin, and capecitabine	docetaxel, nedaplatin, and capecitabine	Sun Yat-sen University	phase 3	Taxane, Platinum-based DNA crosslinker, Thymidylate synthase inhibitor	Microtubules, DNA, Thymidylate synthase
Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab	Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab	Lee's Pharmaceutical Limited	phase 3	PD-1 inhibitor, VEGF inhibitor, microtubule inhibitor, platinum-based DNA crosslinking agent	PD-1, VEGF, microtubules, DNA
Gemcitabine, Vinorelbine, Eribulin, or Utidelone	Gemcitabine, Vinorelbine, Eribulin, or Utidelone	Sun Yat-sen University	phase 3	Chemotherapy combination (nucleoside analog, vinca alkaloid, microtubule inhibitor, microtubule stabilizer)	Multiple: ribonucleotide reductase, microtubules, DNA synthesis
epidoxorubicine, docetaxel, cyclophosphamide	epidoxorubicine, docetaxel, cyclophosphamide	Sanofi	phase 3	anthracycline antibiotic, taxane, alkylating agent	topoisomerase II, microtubules, DNA
cyclophosphamide, vincristine, prednisone, dacarbazine	cyclophosphamide, vincristine, prednisone, dacarbazine	University of Giessen	phase 3	Alkylating agent, Vinca alkaloid, Corticosteroid	Microtubules, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vinca alkaloid, platinum-based alkylating agent, topoisomerase inhibitor class)

1. St. Jude Children's Research Hospital · 1 drug in this class